Novo Nordisk has announced that the European Commission has granted marketing authorisation for Saxenda (liraglutide 3 mg) for the treatment...
Novo Nordisk has announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue,...
Objective: Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable cardiovascular risk factor and emerging therapeutic target. Liraglutide, an analog of glucagon-like peptide-1, is indicated ...
We sought to determine the efficacy of high-dose liraglutide (3.0 mg once daily) in patients with prior bariatric surgery.
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
Pooled post-hoc analysis results from the SCALE Obesity and Prediabetes, and SCALE Diabetes trials demonstrated that at 56 weeks, people...
The FDA has approved the New Drug Application (NDA) for Saxenda (liraglutide 3 mg), from Novo Nordisk, the first once-daily...
This guideline, relating to the provision of a percutaneously placed enteral tube feeding service, is focused upon a specific area of nutrition provision that has not been previously targeted.
To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.